论文部分内容阅读
目的:探讨ABCG2及CD133蛋白在宫颈癌的表达及临床意义。方法:用免疫组化SP法检测92例宫颈癌、40例宫颈上皮内瘤变(CIN)和30例正常宫颈组织中AB-CG2及CD133蛋白的表达。结果:ABCG2在宫颈癌、CIN和正常宫颈组织的阳性表达率分别为69.6%、42.5%、23.3%,CD133为57.6%、37.5%、23.3%,两者在宫颈癌的表达均高于CIN及正常组织,差异均有统计学意义(P<0.05);两者表达与宫颈癌患者年龄、肿瘤大小、临床分期无相关性(P>0.05),而在不同分化组间表达的差异有统计学意义(P<0.05)。结论:ABCG2和CD133蛋白异常表达与宫颈癌的发生、发展有关,二者联合检测可作为评估宫颈癌恶性程度、指导治疗的重要参考指标。
Objective: To investigate the expression and clinical significance of ABCG2 and CD133 in cervical cancer. Methods: The expressions of AB-CG2 and CD133 in 92 cases of cervical cancer, 40 cases of cervical intraepithelial neoplasia (CIN) and 30 cases of normal cervical tissue were detected by immunohistochemical SP method. Results: The positive rates of ABCG2 in cervical cancer, CIN and normal cervical tissues were 69.6%, 42.5%, 23.3%, 57.6%, 37.5% and 23.3%, respectively. The expression of ABCG2 in cervical cancer was higher than that in CIN (P <0.05). There was no correlation between the expression and the age, tumor size and clinical stage of cervical cancer (P> 0.05), but the difference between the two groups was statistically significant Significance (P <0.05). Conclusion: Abnormal expression of ABCG2 and CD133 proteins is related to the occurrence and development of cervical cancer. The combined detection of ABCG2 and CD133 proteins may be used as an important reference index for evaluating the malignancy and guiding treatment of cervical cancer.